NEWS

Major supporter of N-deal won't seek re-election

Source:PTI
January 03, 2008

United States' Californian Democrat Tom Lantos, who played a crucial role in the passage of Henry Hyde Act on the India-United States civil nuclear deal, has decided to not to seek re-election for a 15th term in November due to medical reasons.

"Routine medical tests have revealed that I have cancer of the oesophagus. In view of this development and the treatment it will require, I will not seek re-election," Lantos, also the chairman of the House Foreign Affairs Committee said.

The Californian Democrat was one of the critical law makers involved in the passage of the Henry Hyde Act of 2006 on the Indo-US nuclear deal. A strong supporter of India, he had made no bones of his displeasure on New Delhi's relations with Iran.

Lantos was elected to Congress in 1980 and is in his 14th term in office. He is also a senior member of the House Committee on Oversight and Government Reform.

"It is only in the US that a penniless survivor of the Holocaust and a fighter in the anti-Nazi underground could have received an education, raised a family, and had the privilege of serving the last three decades of his life as a Member of Congress. I will never be able to express fully my profoundly felt gratitude to this great country," Lantos said.

The only Holocaust survivor ever elected to Congress, Lantos is the founding co-chairman of the 24-year-old Congressional Human Rights Caucus, for which Annette has directed as a volunteer since its inception.

"Tom's decision to leave Congress will be deeply felt by his colleagues who value his wisdom, expertise and good judgment," the Republican Ranking Member on the House Foreign Affairs Committee, Ilena Ros-Lehtinen said.

Source: PTI
© Copyright 2024 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.

NEXT ARTICLE

NewsBusinessMoviesSportsCricketGet AheadDiscussionLabsMyPageVideosCompany Email